Get the Stockscreener App
0.00
100.00%
-93.80
After Hours:
2.65
2.65
+
Aerovate Therapeutics Inc stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Aerovate Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing drugs that improve the lives of patients with rare cardiopulmonary disease. The initial focus of the company is on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension.
See More
Previous Close:
$93.80
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$80.00M
Revenue:
-
Net Income/Loss:
$-75.52M
P/E Ratio:
0.00
EPS:
-2.88
Net Cash Flow:
$-56.92M
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$884.98
Aerovate Therapeutics Inc Stock (AVTE) Company Profile
Name
Aerovate Therapeutics Inc
Sector
Industry
Phone
617-443-2400
Address
930 WINTER STREET, WALTHAM
Compare AVTE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AVTE
Aerovate Therapeutics Inc
|
0.00 | 80.00M | 0 | -75.52M | -56.92M | -2.88 |
|
ONC
Beigene Ltd Adr
|
236.49 | 23.78B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.32 | 108.15B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.24 | 43.44M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
604.62 | 61.69B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
74.09 | 5.72B | 0 | -153.72M | -103.81M | -2.00 |
Aerovate Therapeutics Inc Stock (AVTE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-07-25 | Initiated | Wedbush | Outperform |
| May-05-25 | Initiated | Stifel | Buy |
| May-02-25 | Initiated | TD Cowen | Buy |
| Jun-18-24 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-18-24 | Downgrade | TD Cowen | Buy → Hold |
| Jun-18-24 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jun-17-24 | Downgrade | BTIG Research | Buy → Neutral |
| Jun-17-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-17-24 | Downgrade | Wedbush | Outperform → Neutral |
| Mar-25-24 | Resumed | Jefferies | Buy |
| Dec-08-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Dec-06-22 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-19-22 | Resumed | Wedbush | Outperform |
| Aug-16-22 | Downgrade | BTIG Research | Buy → Neutral |
| Feb-11-22 | Initiated | BTIG Research | Buy |
| Jul-26-21 | Initiated | Cowen | Outperform |
| Jul-26-21 | Initiated | Evercore ISI | Outperform |
| Jul-26-21 | Initiated | Jefferies | Buy |
| Jul-26-21 | Initiated | Wedbush | Outperform |
View All
Aerovate Therapeutics Inc Stock (AVTE) Latest News
Aerovate Therapeutics (AVTE) to Release Earnings on Monday - Defense World
Renaissance Technologies LLC Buys 26,700 Shares of Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Stifel Nicolaus Initiates Coverage on Jade Biosciences With Buy Rating, $19 Price Target - marketscreener.com
JPMorgan Chase & Co. Has $178,000 Position in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates AVTE and PFIE on Behalf of Shareholders - marketscreener.com
Aerovate Therapeutics, Inc. Announces Board Changes - marketscreener.com
Aerovate Therapeutics Declares Special Cash Dividend In Connection With The Proposed Merger With Jade Biosciences - marketscreener.com
TD Cowen Initiates Coverage on Jade Biosciences With Buy Rating - marketscreener.com
Aerovate Therapeutics Completes Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Announces Range of Expected Cash Dividend - marketscreener.com
Aerovate Therapeutics Announces Range Of Expected Cash Dividend - marketscreener.com
RTW Biotech Opportunities’ Jade Biosciences merges with Aerovate Therapeutics - QuotedData
Jade Biosciences Highlights JADE-001 Progress in Presentation - TipRanks
Aerovate Therapeutics Inc (AVTE)’s financial ratios: A comprehensive overview - DWinneX
Aerovate Therapeutics (AVTE) Options Set for Delisting | AVTE St - GuruFocus
Aerovate Therapeutics (AVTE) Options Set for Delisting | AVTE Stock News - GuruFocus
Traders Buy Large Volume of Call Options on Aerovate Therapeutics (NASDAQ:AVTE) - Defense World
Jade Biosciences closes merger with Aerovate Therapeutics - Business in Vancouver
Aerovate Therapeutics Inc (AVTE) gets rating Downgrade from Wells Fargo - knoxdaily.com
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously ... - Bluefield Daily Telegraph
Jade Biosciences Completes Closing of Merger with Aerovate - GlobeNewswire
Jade Biosciences Completes Closing of Merger with Aerovate Therapeutics and Previously Announced Private Placement of Approximately $300 Million - Benzinga
Russell Investments Group Ltd. Boosts Stake in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) - Defense World
Aerovate Therapeutics, Inc. SEC 10-Q Report - TradingView
Aerovate Therapeutics Inc (AVTE) Performance and Fundamentals Dashboard tells a completely different story - Sete News
AVTE’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Aerovate Therapeutics Presents Phase 1 Data for AV-101, A Novel Dry Powder Inhaled Formulation of Imatinib Being Developed for the Treatment of Patients with Pulmonary Arterial Hypertension (PAH) - Barchart.com
AVTE Shares Experience Decline in Value - knoxdaily.com
Aerovate (AVTE) Approves 1-for-35 Reverse Stock Split Amid Merge - GuruFocus
Aerovate approves reverse split ahead of Jade merger By Investing.com - Investing.com South Africa
Aerovate Therapeutics and Jade Biosciences Merger Approved - citybiz
Aerovate Stockholders Approve Merger Proposal With Jade Biosciences - Nasdaq
Aerovate approves reverse split ahead of Jade merger - Investing.com
Aerovate (AVTE) Stockholders Approve Merger with Jade Biosciences | AVTE Stock News - GuruFocus
Aerovate Therapeutics Approves Merger with Jade Biosciences - TipRanks
Aerovate Therapeutics stockholders approve proposed merger with Jade Biosciences - TipRanks
Aerovate Therapeutics Stockholders Approve Proposed Merger With Jade Biosciences And All Related Proposals - marketscreener.com
Aerovate Therapeutics Stockholders Approve Proposed Merger with Jade Biosciences and All Related Proposals - PR Newswire
Halper Sadeh LLP, Aerovate Therapeutics, Inc., Staffing 360 Solutions, Inc., Allovir - The Bradford Era
Aerovate announces $69.6 million special dividend By Investing.com - Investing.com India
Aerovate Therapeutics Declares Special Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - The Malaysian Reserve
Aerovate announces $69.6 million special dividend - Investing.com Australia
Aerovate signals cash dividend ahead of Jade merger By Investing.com - Investing.com South Africa
Aerovate Therapeutics Stock Bucks Broader Market Sell-Off Over Dividend Announcement: Stock Rises But Retail’s Unmoved - NewsBreak: Local News & Alerts
Aerovate Therapeutics Announces Merger with Jade Biosciences - TipRanks
Aerovate signals cash dividend ahead of Jade merger - Investing.com
Aerovate Therapeutics Announces Range of Expected Cash Dividend in Connection with the Proposed Merger with Jade Biosciences - PR Newswire
36,897 Shares in Aerovate Therapeutics, Inc. (NASDAQ:AVTE) Acquired by Corient Private Wealth LLC - Defense World
$TOCKHOLDER ALERT: The M&A Class Action Firm Encourages Shareholders of AMPY, HEES, AVTE, TGI to Act - The Malaysian Reserve
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates TGI, AV - GuruFocus
Aerovate Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Aerovate Therapeutics Inc Stock (AVTE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.52%
1.15%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):